TITLE

Summary Basis of Decision in context

AUTHOR(S)
Gorman, Diane
PUB. DATE
June 2005
SOURCE
CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1664
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Presents a letter to the editor in response to the article "Transparency in Drug Regulation: Mirage or Oasis?," by Joel Lexchin and Barbara Mintzes, which appeared in a 2004 issue of the "Canadian Medical Association Journal."
ACCESSION #
17290884

 

Related Articles

  • Avoiding Pitfalls. Spilker, Bert // Applied Clinical Trials;May2009, Vol. 18 Issue 5, p14 

    A letter to the editor is presented in response to the article "Guide to Drug Development: A Comprehensive Review & Assessment," by Bert Spilker, published by Lippincott, Williams & Wilkins.

  • Consistency of gonadotrophin products. Bassett, R. M. // Reproductive BioMedicine Online;Jul2005, Vol. 11 Issue 1, p117 

    Presents a letter to the editor about the manufacturing process for follitropin alfa.

  • What's So Great About Newness? Light, Donald W. // Health Affairs;Nov/Dec2007, Vol. 26 Issue 6, p1793 

    A letter to the editor is presented in response to the article about the variable of newness as a valid measure of therapeutic gain and money saved by using newer drugs by Frank Lichtenberg in the May/June 2007 issue.

  • Newness: The Author Responds. Lichtenberg, Frank R. // Health Affairs;Nov/Dec2007, Vol. 26 Issue 6, p1793 

    A response by Frank Lichtenberg to a letter to the editor about his article the variable of newness as a valid measure of therapeutic gain and money saved by using newer drugs in the May and June 2007 issue is presented.

  • Nonprofit Drug Companies. Klein, Benjamin E.; Daldy, Kathryn J. // Health Affairs;Nov/Dec2005, Vol. 24 Issue 6, p1684 

    Presents a letter to the editor regarding an article about the non-profit pharmaceutical organizations' model for drug-development, published in the July/August 2005 issue of the journal "Health Affairs."

  • A Much Wider Scope. Kleist, Peter // Applied Clinical Trials;Jun2009, Vol. 18 Issue 6, p14 

    A letter to the editor is presented in response to the article "Strategy First," in the May 2009 issue.

  • Good faith gone bad-gone good again. Bialy, Harvey // Nature Biotechnology;Jan2005, Vol. 23 Issue 1, p17 

    Presents a letter to the editor about various problems that can arise when collaborations between multinational pharmaceutical companies and research institutes in developing countries go awry, published in the journal "Nature Biotechnology."

  • Defending CROs. Assandri, Alessandro // Applied Clinical Trials;Apr2008, Vol. 17 Issue 4, p13 

    A letter to the editor is presented in response to the article regarding the significance of clinical research organizations (CRO) to new drugs developed by big pharmaceutical companies.

  • Drug discovery. Pinnock, Rob // New Scientist;4/21/2007, Vol. 194 Issue 2600, p20 

    A letter to the editor is presented in response to an article by Angela Saini in the March 31, 2007 issue.

  • Drug discovery. Chech, Dusan // New Scientist;4/21/2007, Vol. 194 Issue 2600, p20 

    A letter to the editor is presented in response to Angela Saini's article in the March 31, 2007 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics